Kavita Vyas Dharmarajan

Kavita Vyas Dharmarajan

Auto-generated profile, based on publicly available information

Kavita Vyas Dharmarajan

Department of Radiation Oncology, Mount Sinai Hospital, New York, NY

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2017 in BioMed Research International
Verified
Journal Article
Open access
PDF file
SCSanders Chang
Sanders Chang
NGNathan E. Goldstein
Nathan E. Goldstein
KDKavita V. Dharmarajan
Kavita V. Dharmarajan
Older adults with cancer present a unique set of management complexities for oncologists and radiation oncologists. Prognosis and resilience to cancer treatments are notably dependent on the presence or risk of “geriatric syndromes,” in addition to cancer stage and histology. Recognition, proper evaluation, and management of these conditions in conjunction with management of the cancer itself are critical and can be accomplished by utilization of various geriatric assessment tools. Here we review principles of the geriatric assessment, common geriatric syndromes, and application of these concepts to multidisciplinary oncologic treatment. Older patients may experience toxicities related to treatments that impact treatment effectiveness, quality of life, treatment-related mortality, and treatment compliance. Treatment-related burdens from radiotherapy are increasingly important considerations and include procedural demands, travel, costs, and temporary or permanent loss of functional independence. An overall approach to delivering radiotherapy to an older cancer patient requires a comprehensive assessment of both physical and nonphysical factors that may impact treatment outcome. Patient and family-centered communication is also an important part of developing a shared understanding of illness and reasonable expectations of treatment.

25 April 2020 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
MMMadhu Mazumdar
Madhu Mazumdar
JLJung-Yi Joyce Lin
Jung-Yi Joyce Lin
WZWei Zhang
Wei Zhang
Lihua LiLihua Li
Lihua Li
MLMark Liu
Mark Liu
Liangyuan HuLiangyuan Hu
Liangyuan Hu
Background: The Oncology Care Model (OCM) was developed as a payment model to encourage participating practices to provide better-quality care for cancer patients at a lower cost. The risk-adjustment model used in OCM is a Gamma generalized linear model (Gamma GLM) with log-link. The predicted value of expense for the episodes identified for our academic medical center (AMC), based on the model fitted to the national data, did not correlate well with our observed expense. This motivated us to fit the Gamma GLM to our AMC data and compare it with two other flexible modeling methods: Random Forest (RF) and Partially Linear Additive Quantile Regression (PLAQR). We also performed a simulation study to assess comparative performance of these methods and examined the impact of non-linearity and interaction effects, two understudied aspects in the field of cost prediction. Methods: The simulation was designed with an outcome of cost generated from four distributions: Gamma, Weibull, Log-normal with a heteroscedastic error term, and heavy-tailed. Simulation parameters both similar to and different from OCM data were considered. The performance metrics considered were the root mean square error (RMSE), mean absolute prediction error (MAPE), and cost accuracy (CA). Bootstrap resampling was utilized to estimate the operating characteristics of the performance metrics, which were described by boxplots. Results: RF attained the best performance with lowest RMSE, MAPE, and highest CA for most of the scenarios. When the models were misspecified, their performance was further differentiated. Model performance differed more for non-exponential than exponential outcome distributions. Conclusions: RF outperformed Gamma GLM and PLAQR in predicting overall and top decile costs. RF demonstrated improved prediction under various scenarios common in healthcare cost modeling. Additionally, RF did not require prespecification of outcome distribution, nonlinearity effect, or interaction terms. Therefore, RF appears to be the best tool to predict average cost. However, when the goal is to estimate extreme expenses, e.g., high cost episodes, the accuracy gained by RF versus its computational costs may need to be considered.

1 May 2019 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
ZGZahra Ghiassi-Nejad
Zahra Ghiassi-Nejad
MRMeng Ru
Meng Ru
EMErin Moshier
Erin Moshier
SCSanders Chang
Sanders Chang
SJSundar Jagannath
Sundar Jagannath
KDKavita Dharmarajan
Kavita Dharmarajan

1 June 2018 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
SCSanders Chang
Sanders Chang
PMPeter May
Peter May
NGNathan E. Goldstein
Nathan E. Goldstein
JWJuan Wisnivesky
Juan Wisnivesky
DRDoran Ricks
Doran Ricks
KDKavita V. Dharmarajan
Kavita V. Dharmarajan

1 July 2017 in Practical Radiation Oncology
Verified
Journal Article
Closed access
RWRandy L. Wei
Randy L. Wei
LCLauren E. Colbert
Lauren E. Colbert
JJJoshua Jones
Joshua Jones
MRMargarita Racsa
Margarita Racsa
GKGabrielle Kane
Gabrielle Kane
KDKavita V. Dharmarajan
Kavita V. Dharmarajan

1 December 2019 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
KDKavita V. Dharmarajan
Kavita V. Dharmarajan
CWChasity B. Walters
Chasity B. Walters
TLTomer T. Levin
Tomer T. Levin
CMCarol Ann Milazzo
Carol Ann Milazzo
CMChristopher Monether
Christopher Monether
BMBeryl McCormick
Beryl McCormick